PMA device
Heparin-Induced Extracorporeal Lipoprotein Precipitation (H.e.l.p.) Futura Apheresis System
B. Braun Avitum AG · Lipoprotein, Low Density, Removal (MMY, Class III) · First FDA decision Jan 13, 2012, newest Jan 13, 2012Coronary artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
3
Naming "Heparin-Induced Extracorporeal"
MAUDE reports
0
Brand "Heparin-Induced Extracorporeal", since 2015
PubMed studies
110
Mentioning "Heparin-Induced Extracorporeal"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Heparin-Induced Extracorporeal Lipoprotein Precipitation (H.e.l.p.) Futura Apheresis System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HEPARIN-INDUCED EXTRACORPOREAL LIPOPROTEIN PRECIPITATION (H.E.L.P.) FUTURA APHERESIS SYSTEMPMA supplement
P940016-S014 · Decided Jan 13, 2012 · 178 days after receipt · Normal 180 Day Track
Device type: Lipoprotein, low density, removal (MMY) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Heparin-Induced Extracorporeal", any status and sponsor, newest update first.
- (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) CholesterolCompleted
B. Braun Medical Inc.Not on our public-company list
NCT00526058 · 18 participants · Start Aug 2007 · Primary completion Oct 2008
Device: Secura then Futura; Futura then Secura · For: Hypercholesterolemia
Sites: Hartford, Connecticut; Kansas City, Kansas
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Heparin-Induced Extracorporeal", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MMY
19 reports: 1 malfunction, 16 injury, 2 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Heparin-Induced Extracorporeal"[tiab]. The summary above synthesizes these.
- [Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].
Horstkotte D, Mellwig KP · Z Kardiol · 2003English Abstract, Review
- Heparin-induced extracorporeal low-density lipoprotein precipitation.
Mellwig KP · Ther Apher Dial · 2003Review
- The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19.
Jaeger BR, Arron HE, Kalka-Moll WM, et al. · Front Cardiovasc Med · 2022
- Hyperlipoprotein(a)aemia in nephrotic syndrome.
Thiery J, Ivandic B, Bahlmann G, et al. · Eur J Clin Invest · 1996Case Reports
- Heparin-induced extracorporeal low-density lipoprotein precipitation and low-density lipoprotein chemoadsorption onto dextran sulfate: a comparison.
Bosch Y · Artif Organs · 1996Comparative Study, Review
- Recent advances in therapeutic apheresis.
Bosch T · J Artif Organs · 2003Review
- A practical approach for the treatment of post-COVID symptoms.
Heitmann J, Kreutz J, Aldudak S, et al. · Herz · 2023
- Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a).
Waldmann E, Parhofer KG · Pathology · 2019Review
- Lipoprotein apheresis to treat elevated lipoprotein (a).
Waldmann E, Parhofer KG · J Lipid Res · 2016Review
- Low-density lipoprotein apheresis: an overview.
Bambauer R, Schiel R, Latza R · Ther Apher Dial · 2003Comparative Study, Review
- Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report.
Russi G, Furci L, Leonelli M, et al. · J Med Case Rep · 2009
- HELP-(Heparin-induced Extracorporeal LDL Precipitation)-apheresis in heart recipients with cardiac allograft vasculopathy and concomitant hypercholesterolemia: Influence of long-term treatment on the microcirculation.
Park JW, Matschke K, Mrowietz C, et al. · Clin Hemorheol Microcirc · 2019
Other devices of this type
Also filed under product code MMY.
- Liposorber(R) LA-15 System Adsorption ColumnKaneka Pharma America Corp. · PMA 2025
- H.e.l.p. Plasmat Futura SystemB. Braun Avitum AG · PMA 2015
- Blood Tubing System for the Liposorber LA-15 SystemKaneka Pharma America Corp. · PMA 2010
- B.braun,s Heparin-Induced Extracorporeal Lipoprotein Precipitation (H.e.l.p) SystemB. Braun Avitum AG · PMA 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.